Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Corautus progresses VEGF-2 research
Under the agreement, Corautus will provide its proprietary vascular endothelial growth factor, VEGF-2, to Caritas St Elizabeth’s Medical Center (CSEMC) for evaluation. The phase I trial at CSEMC
Under the agreement, Corautus will provide its proprietary vascular endothelial growth factor, VEGF-2, to Caritas St Elizabeth’s Medical Center (CSEMC) for evaluation. The phase I trial at CSEMC
The study will evaluate on an ongoing basis the ability of higher doses of Riquent to further reduce antibodies to double-stranded DNA (dsDNA). Antibodies to dsDNA are associated
Macugen (pegaptanib sodium injection) is a novel treatment for neovascular age-related macular degeneration (AMD). The drug was acquired by OSI late last year as part of its purchase
The results from the phase I portion of a phase I/II dose-escalation study of glufosfamide in combination with gemcitabine, marketed by Eli Lilly under the brand name Gemzar,
The mouse version of the drug, called 3G4, was effective at controlling the growth and spread of pancreatic cancer as a single agent and had significantly enhanced efficacy
Vitro has previously developed 29 adult pancreatic stem cell lines and has developed methodologies to induce differentiation of functional human beta cells from these cell lines. PhosphoSolutions makes
The results of the investigation demonstrate the safety and potential efficacy of Novagali’s treatment, called Nova22007, in patients suffering from Sjogren syndrome. This syndrome is a type of
If all shareholders of Berna tender their shares and the exchange offer is declared successful, Crucell will issue up to a maximum of 18,000,000 ordinary shares to the
Amplimexon is also currently in phase I/II clinical trials evaluating safety and efficacy in a number of cancers, including pancreatic, lung, breast, prostate, and multiple myeloma. The drug
As well as the 95% survival rate at the median 9.2 year follow-up, 45% of patients that received the vaccine remained in continuous first clinical remission at their